38 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
25
Ending by 2030
Jan 2027
Next term end
19
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2028 · High confidence
Also notable
Ends Feb 2029 · High confidence
Also notable
Ends Dec 2028 · High confidence
Also notable
Ends Mar 2032 · High confidence
Also notable
Ends Sep 2032 · High confidence
Also notable
Ends Sep 2027 · High confidence
Also notable
Ends Aug 2031 · High confidence
Also notable
Ends Oct 2032 · High confidence
Gene Defects and Mutant Alk Kinase in Human Solid Tumors
US 7,700,339
The largest patent family in this portfolio, 13 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Production of motif-specific and context-independent antibodies using peptide libraries as antigens
US 9,085,609
The largest patent family in this portfolio, 16 related applications, renewed at every maintenance window due so far. Protection runs to 2029.
Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma
US 8,383,799
The largest patent family in this portfolio, 19 related applications, renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Methods and Reagents for Creating Monoclonal Antibodies
US 9,920,110
Cited by 18 later US patents, top 25% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2032.
Mass spectroscopy analysis of mutant polypeptides in biological samples
US 9,453,845
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2032.
Reagents for the Detection of Protein Phosphorylation in Signaling Pathways
US 7,999,080
Renewed at every maintenance window since the 2011 grant; no more fees are due before its term ends in 2027.
Methods of Detecting a Polypeptide Having Anaplastic Lymphoma Kinase Activity in Kidney Cancer
US 10,551,383
Granted 2020. Computed term ends 2031.
Multi Component Antibody Based Detection Technology
US 9,588,110
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 21, 2027The maintenance fee for Production of motif-specific and context-independent antibodies using peptide libraries as antigens (US 9,085,609) comes due Jan 21, 2027. Unpaid by Jul 21, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Shower Plate and Substrate Processing Apparatus (US 9,136,097) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma (US 10,526,661) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 2 fees due Aug 2 to 4, 2027 · next Aug 2
- 1 fee due Sep 3, 2027The maintenance fee for Multi Component Detection (US 10,577,640) comes due Sep 3, 2027. Unpaid by Mar 3, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma (US 9,328,349) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 22, 2026
- Aug 30 US 11,428,696 Mass Spectrometry Analysis of Mutant Polypeptides in Biological Samples · lapsed on the fee record
What they patent
The largest of its 19 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,099,188 | Ros Kinase in Lung Cancer In force · Medium confidence | In force | Medium confidence | |
| US 11,761,005 | Translocation and Mutant Ros Kinase in Human Non-Small Cell Lung Carcinoma In force · High confidence | In force | High confidence | |
| US 8,168,383 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence | In force | High confidence | |
| US 8,288,102 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence | In force | High confidence | |
| US 8,377,642 | Gene Defects and Mutant Alk Kinase in Human Solid Tumors In force · High confidence | In force | High confidence | |
| US 9,523,130 | Methods of Treating Non-Small Cell Lung Carcinoma (NSCLC) In force · Medium confidence | In force | Medium confidence | |
| US 9,988,688 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer In force · High confidence | In force | High confidence | |
| US 10,870,892 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer In force · High confidence | In force | High confidence | |
| US 10,955,416 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Human Lung Cancer In force · Medium confidence | In force | Medium confidence | |
| US 11,505,833 | Compositions for Detecting Mutant Anaplastic Lymphoma Kinase in Lung Cancer In force · High confidence | In force | High confidence |
Also on record, not counted in the 38: 1 patent in force now held by others · 16 patents ended · 1 application pending · 69 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.